Palbociclib in HR-Positive, HER2-Negative Advanced/Metastatic Breast Cancer: A Systematic Scoping Review of Real-World Evidence from Countries Outside of Western Regions That Are Underrepresented in Clinical Trials

Overview

Journal Oncol Ther

Specialty Oncology

Date 2024 Aug 2

PMID 39095679

Authors

Amit Rauthan

Ankita Jain

Manmohan Singh

Mehmet A N Sendur

Affiliations

Soon will be listed here.

Abstract

Introduction: Limited awareness exists regarding real-world data (RWD) for palbociclib in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced/metastatic breast cancer in populations from certain countries outside of Western regions.

Methods: A systematic scoping review was conducted using PubMed and Embase to evaluate RWD for palbociclib from countries outside of Western regions that are underrepresented in clinical trials. Search criteria were aligned with our research question for relevant English-language publications, without restrictions on publication date, followed by Phase 1 (title and abstract) and Phase 2 (full-text) screening of retrieved citations as per Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Data analyses of eligible studies were done separately for abstracts and full-text publications to enhance the precision and reliability of the results.

Results: Database search yielded 1485 non-duplicate records, 46 qualified for inclusion, of which 47.8% were published as full text. The analysis of outcomes, based exclusively on full-text publications that collectively included 2048 patients treated with palbociclib, revealed the median progression-free survival (PFS) of 20.2-36.7 months, overall survival (OS) of 39.9 months (reported in one publication) and objective response rate (ORR) of 45.3-80.0% with first-line treatment. In ≥ second line, the median PFS, OS and ORR ranged from 7.0 to 24.2 months, 11 to 19.6 months, and 13.9% to 47.9%, respectively. The safety profile of palbociclib was similar to that reported in pivotal clinical studies, and no new safety concerns were identified.

Conclusions: A comprehensive volume of evidence demonstrates that palbociclib's effectiveness and safety profile in real-world settings align with those observed in clinical trials, offering valuable insights for clinical decision-making in countries outside of Western regions underrepresented in clinical trials.

References

Barrios C, de Lima Lopes G, Yusof M, Rubagumya F, Rutkowski P, Sengar M . Barriers in access to oncology drugs - a global crisis. Nat Rev Clin Oncol. 2022; 20(1):7-15. PMC: 9665041. DOI: 10.1038/s41571-022-00700-7. View

Jadoo S, Aljunid S, Sulku S, Nur A . Turkish health system reform from the people's perspective: a cross sectional study. BMC Health Serv Res. 2014; 14:30. PMC: 3932508. DOI: 10.1186/1472-6963-14-30. View

Odan N, Kikawa Y, Matsumoto H, Minohata J, Suwa H, Hashimoto T . Real-World Outcomes of Treating Advanced Breast Cancer Patients With Palbociclib: A Multicenter Retrospective Cohort Study in Japan-The KBCOG-14 Study. Breast Cancer (Auckl). 2021; 14:1178223420983843. PMC: 7780165. DOI: 10.1177/1178223420983843. View

Ganguly S, Mukherjee N, Mandal S, Roy S, Agarwal S, Biswas B . Efficacy of cyclin-dependent kinase 4/6 inhibitors in patients with metastatic hormone positive breast cancer: a single institutional study from India. Ecancermedicalscience. 2022; 16:1450. PMC: 9666281. DOI: 10.3332/ecancer.2022.1450. View

Saini K, Twelves C . Determining lines of therapy in patients with solid cancers: a proposed new systematic and comprehensive framework. Br J Cancer. 2021; 125(2):155-163. PMC: 8292475. DOI: 10.1038/s41416-021-01319-8. View

Shen L, Zhou J, Chen Y, Ding J, Wei H, Liu J . Treatment patterns, effectiveness, and patient-reported outcomes of palbociclib therapy in Chinese patients with advanced breast cancer: A multicenter ambispective real-world study. Cancer Med. 2022; 11(22):4157-4168. PMC: 9678098. DOI: 10.1002/cam4.4767. View

Bruno L, Ostinelli A, Waisberg F, Enrico D, Ponce C, Rivero S . Cyclin-Dependent Kinase 4/6 Inhibitor Outcomes in Patients With Advanced Breast Cancer Carrying Germline Pathogenic Variants in DNA Repair-Related Genes. JCO Precis Oncol. 2022; 6:e2100140. DOI: 10.1200/PO.21.00140. View

Brufsky A, Gallagher C . P-REALITY X: A Real-World Analysis of Palbociclib Plus an Aromatase Inhibitor in HR+/HER2- Metastatic Breast Cancer-A Podcast. Target Oncol. 2023; 18(3):321-326. PMC: 10192186. DOI: 10.1007/s11523-023-00968-4. View

Im S, Gennari A, Park Y, Kim J, Jiang Z, Gupta S . Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, staging and treatment of patients with metastatic breast cancer. ESMO Open. 2023; 8(3):101541. PMC: 10186487. DOI: 10.1016/j.esmoop.2023.101541. View

10.

Kraus A, Yu-Kite M, Mardekian J, Cotter M, Kim S, Decembrino J . Real-World Data of Palbociclib in Combination With Endocrine Therapy for the Treatment of Metastatic Breast Cancer in Men. Clin Pharmacol Ther. 2021; 111(1):302-309. DOI: 10.1002/cpt.2454. View

11.

Palmieri C, Musson A, Harper-Wynne C, Wheatley D, Bertelli G, Macpherson I . A real-world study of the first use of palbociclib for the treatment of advanced breast cancer within the UK National Health Service as part of the novel Ibrance® Patient Program. Br J Cancer. 2023; 129(5):852-860. PMC: 10449843. DOI: 10.1038/s41416-023-02352-5. View

12.

DeMichele A, Robert N, Chen C, Kim S, Zhang Z, Lu D . Real-World Tumor Response of Palbociclib in Combination With an Aromatase Inhibitor as First-Line Therapy in Pre/Perimenopausal Women With Metastatic Breast Cancer. Target Oncol. 2023; 18(4):543-558. PMC: 10345062. DOI: 10.1007/s11523-023-00979-1. View

13.

Palmieri C, Owide J, Fryer K . Estimated Prevalence of Metastatic Breast Cancer in England, 2016-2021. JAMA Netw Open. 2022; 5(12):e2248069. PMC: 9857429. DOI: 10.1001/jamanetworkopen.2022.48069. View

14.

Mycock K, Zhan L, Hart K, Taylor-Stokes G, Milligan G, Atkinson C . Real-world treatment of patients with palbociclib for HR+/HER2-advanced/metastatic breast cancer: the Europe IRIS study. Future Oncol. 2021; 18(3):349-362. DOI: 10.2217/fon-2021-0716. View

15.

Shangguan C, Jiang M, Yang C, Lou G, Li Y, Qu Q . Clinical efficacy of palbociclib-based therapy in women with HR+/HER2- metastatic breast cancer in the real-world setting for Chinese women: a comparison with the IRIS study. Eur Rev Med Pharmacol Sci. 2021; 25(19):6138-6148. DOI: 10.26355/eurrev_202110_26892. View

16.

Lee J, Park H, Won H, Yang J, Lee H, Woo I . Real-World Clinical Data of Palbociclib in Asian Metastatic Breast Cancer Patients: Experiences from Eight Institutions. Cancer Res Treat. 2020; 53(2):409-423. PMC: 8053880. DOI: 10.4143/crt.2020.451. View

17.

Loi S, Karapetis C, McCarthy N, Oakman C, Redfern A, White M . Palbociclib plus letrozole as treatment for postmenopausal women with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer for whom letrozole therapy is deemed appropriate: An expanded access study in.... Asia Pac J Clin Oncol. 2021; 18(6):560-569. PMC: 9787838. DOI: 10.1111/ajco.13653. View

18.

Rajappa S, Singh M, Uehara R, Schachterle S, Setia S . Cancer incidence and mortality trends in Asia based on regions and human development index levels: an analyses from GLOBOCAN 2020. Curr Med Res Opin. 2023; 39(8):1127-1137. DOI: 10.1080/03007995.2023.2231761. View

19.

Bao K, Sutanto L, Tse S, Man Cheung K, Chan J . The Association of ERBB2-Low Expression With the Efficacy of Cyclin-Dependent Kinase 4/6 Inhibitor in Hormone Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer. JAMA Netw Open. 2021; 4(11):e2133132. PMC: 8571658. DOI: 10.1001/jamanetworkopen.2021.33132. View

20.

Beachler D, de Luise C, Jamal-Allial A, Yin R, Taylor D, Suzuki A . Real-world safety of palbociclib in breast cancer patients in the United States: a new user cohort study. BMC Cancer. 2021; 21(1):97. PMC: 7831235. DOI: 10.1186/s12885-021-07790-z. View